Clinical trials: sargramostim
Melanoma
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
The purpose of this study is to learn about the safety and the risks of using talimogene laherparepvec in patients who already received treatment with talimogene laherparepvec in study 005/05 (NCT00769704), and to see if extended…
- Trial name
- NCT01368276
- Testing
- Talimogene Laherparepvec, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 31 people
- Sponsor
- BioVex Limited
Metastatic Melanoma
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
This is an open label, single-arm, phase IB treatment study to determine the safety of administering anti-PD1 monoclonal antibodies with AV-MEL-1 and to get some suggestion of efficacy, in patients with measurable metastatic…
- Trial name
- NCT03743298
- Testing
- AV-MEL-1
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aivita Biomedical, Inc.
Autoimmune Pulmonary Alveolar Proteinosis
Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
The goal of this open-label study is to study molgramostim as a treatment for autoimmune pulmonary alveolar proteinosis (aPAP) in pediatric patients between age 6 and 18.
- Trial name
- NCT06431776
- Testing
- Molgramostim
- Where
- Germany
- Volunteers
- 5 people
- Sponsor
- Savara Inc.
Glioblastoma, Gliosarcoma
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
This phase II clinical trial studies how well ERC1671 plus Granulocyte-macrophage colony-stimulating factor (GM-CSF) plus Cyclophosphamide with Bevacizumab works compared to Placebo Injection plus Placebo Pill with Bevacizumab in…
- Trial name
- NCT01903330
- Testing
- ERC1671, GM-CSF, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 84 people
- Sponsor
- Epitopoietic Research Corporation
Mycoses
Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT
We conducted a prospective, multicenter, open-label randomized trial to compare the antifungal effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF), Recombinant Human Granulocyte Stimulating Factor…
- Trial name
- NCT01232504
- Testing
- rhGM-CSF group, rhG-CSF+rhGM-CSF group, rhG-CSF group
- Where
- 5 sites in China
- Volunteers
- 206 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Crohn Disease
Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease
The purpose of this study is to evaluate if Leukine can induce clinical response or remission in patients with Crohn's disease.
- Trial name
- NCT00295165
- Testing
- Sargramostim (Leukine)
- Where
- 111 sites in United States, Australia and 9 more
- Volunteers
- 33 people
- Sponsor
- Genzyme, a Sanofi Company
Solid Tumors, Lung Adenocarcinoma
IBI188 Combination Therapy in Solid Tumors
A Phase Ib study aim to evaluate the efficacy, safety, and tolerability of IBI188 combination therapy in subjects with advanced malignancies
- Conditions
- Solid Tumors, Lung Adenocarcinoma, Osteosarcoma
- Trial name
- NCT04861948
- Testing
- IBI188, GM-CSF, Cisplatin/Carboplatin
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
COVID-19
Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection
This is an adaptive Phase I trial of a vaccine consisting of autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein, with or without GM-CSF, to prevent COVID-19 in adults.
- Trial name
- NCT04690387
- Testing
- AV-COVID-19, GM-CSF
- Where
- Indonesia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Aivita Biomedical, Inc.
Dementia Alzheimer's Type
Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
Primary Objective: To compare the effect of repeat doses of Leukine to placebo administered subcutaneously (SC) on established cortical amyloid load in patients with mild cognitive impairment (MCI) due to Alzheimer's disease…
- Trial name
- NCT02667496
- Testing
- Sargramostim GZ402664, Florbetapir F18
- Where
- United States
- Sponsor
- Sanofi
Non-Hodgkin's Lymphoma
Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma
The treatment being investigated is a patient- and tumor-specific therapy known as a personalized active immunotherapy. Personalized active immunotherapy is an attempt to use a person's own immune system to combat disease.
- Trial name
- NCT00510471
- Testing
- autologous immunoglobulin idiotype-KLH conjugate vaccine
- Where
- 9 sites in United States
- Sponsor
- Genitope Corporation
Lymphoma
Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00258336
- Testing
- autologous immunoglobulin idiotype-KLH conjugate vaccine, rituximab, sargramostim
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Favrille
Renal Cell Carcinoma
IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease
This study was conducted in order to evaluate the efficacy and safety of the cancer vaccine IMA901 and GM-CSF as adjuvant in the treatment of advanced renal cell carcinoma.
- Trial name
- IMA901-202 (NCT00523159)
- Testing
- Endoxana, IMA901, Leukine, IMA901 and Leukine
- Where
- 44 sites in Austria, Bulgaria and 8 more
- Volunteers
- 68 people
- Sponsor
- Immatics Biotechnologies GmbH
Breast Cancer, Metastatic Breast Cancer
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic
- Trial name
- BRIA-ABC (NCT06072612)
- Testing
- SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site
- Where
- 79 sites in United States
- Volunteers
- 404 people
- Sponsor
- BriaCell Therapeutics Corporation
Non-Hodgkins Lymphoma
Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma
The primary objective of this Phase 3 study is to definitively confirm the safety and efficacy of BiovaxId, an autologous tumor derived immunoglobulin idiotype vaccine, as measured by a significant prolongation of the period of…
- Trial name
- BiovaxID (NCT00091676)
- Testing
- FNHLId1, KLH + GM-CSF
- Volunteers
- 629 people
- Sponsor
- Biovest International
Squamous Cell Carcinoma of the Oral Cavity
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
This is a multi-center, randomized, double-blind clinical trial to assess the safety and efficacy of GL-0817 as a means to prevent disease recurrence in patients considered at high-risk following surgery and adjuvant…
- Trial name
- NCT02873819
- Testing
- GL-0817, Hiltonol, Sargramostim
- Where
- 33 sites in United States, Hungary and 5 more
- Volunteers
- 80 people
- Sponsor
- Gliknik Inc.
Crohn's Disease
Study of Sargramostim in Moderately to Severely Active Crohn's Disease
The purpose of this study is to assess the tolerability, pharmacokinetics and safety of 2 and 6 micro g/kg/day sargramostim administered subcutaneously once daily for 4 weeks, and to assess the efficacy and safety of 6 micro…
- Trial name
- NCT00329537
- Testing
- Sargramostim (Leukine)
- Volunteers
- 11 people
- Sponsor
- Genzyme, a Sanofi Company
Lymphoma, Follicular
Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate whether treatment with rituximab plus sargramostim will be more effective than rituximab alone.
- Trial name
- PREMIER (NCT00308087)
- Testing
- Sargramostim (Leukine), Rituximab
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 75 people
- Sponsor
- Genzyme, a Sanofi Company
Triple-Negative Breast Cancer
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of tiragolumab in combination with atezolizumab and chemotherapy in participants with metastatic and early triple-negative breast cancer (TNBC).
- Trial name
- NCT04584112
- Testing
- Tiragolumab, Atezolizumab, Nab-paclitaxel
- Where
- 24 sites in United States, Australia and 6 more
- Volunteers
- 83 people
- Sponsor
- Hoffmann-La Roche
Malignant Melanoma
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
UV1 is a therapeutic cancer vaccine that has been explored in prostate and lung cancers, and in combination with ipilimumab in malignant melanoma.
- Trial name
- NCT03538314
- Testing
- UV1, GM-CSF
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Ultimovacs ASA
Breast Cancer
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
The study will be a multi-center, prospective, randomized, single-blinded, placebo-controlled Phase II trial of Herceptin + NeuVax(TM) vaccine (E75 peptide/granulocyte macrophage-colony stimulating factor) (GM-CSF) versus…
- Trial name
- NCT01570036
- Testing
- Herceptin, NeuVax vaccine, GM-CSF
- Where
- 29 sites in United States
- Volunteers
- 275 people
- Sponsor
- George E. Peoples